Clinical trial
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate…
NCT00003614 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00003614 |
|---|---|
| Title | Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer |
| Official title | Phase II Study of Weekly Paclitaxel by 1-HR Infusion Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | estramustine phosphate sodium, paclitaxel |
| Start date | Feb 4, 1999 |
| Primary completion | Apr 1, 2005 |
| First posted | May 24, 2004 |
| Last update posted | Jun 15, 2023 |
| Countries | South Africa, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: